Combining CA125 and NT-proBNP markedly improves risk prediction for cardiovascular mortality, all-cause mortality, and rehospitalization in acute heart failure (AHF).
High levels of both biomarkers identify patients at substantially elevated risk, supporting their joint use in clinical decision-making.
This prospective Vietnamese cohort provides region-specific evidence for biomarker-guided management in AHF.
